<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345810</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-YMO/TRK-0416</org_study_id>
    <secondary_id>2016-003963-20</secondary_id>
    <secondary_id>ESR-15-11003</secondary_id>
    <secondary_id>AX-CL-NSCLC-AIO-008260</secondary_id>
    <nct_id>NCT03345810</nct_id>
  </id_info>
  <brief_title>Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)</brief_title>
  <acronym>DURATION</acronym>
  <official_title>Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      AIO-YMO/TRK-0416 (DURATION) is a open-label, treatment stratified and randomized phase II
      study of Durvalumab, frail or elderly patients with metastatic non-squamous NSCLC with no
      targetable molecular alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based
      standard-combination chemotherapy but eligible for at-least mono-chemotherapy with
      gemcitabine or vinorelbine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to assess the safety and tolerability of sequential therapy
      consisting of standard of care mono- or combination chemotherapy followed by durvalumab in
      comparison to standard of care mono- or combination chemotherapy in frail/elderly patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of treatment related Grade III/IV adverse events (CTCAE V4.03)</measure>
    <time_frame>through study completion, an average of 24 months</time_frame>
    <description>Comparison of the outcome of sequential therapy consisting of standard of care mono- or combination chemotherapy followed by durvalumab versus standard of care mono- or combination chemotherapy in frail/elderly patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>approx. 24 months</time_frame>
    <description>Progression Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR using assessment according to RECIST 1.1</measure>
    <time_frame>approx. 24 months</time_frame>
    <description>Response Evaluation Criteria In Solid Tumors (RECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>approx. 60 months</time_frame>
    <description>Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events /Serious Adverse Events</measure>
    <time_frame>approx. 48 months</time_frame>
    <description>Adverse Events: Type, incidence, and severity according to NCI CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life (HR-QoL)</measure>
    <time_frame>approx. 60 months</time_frame>
    <description>as determined with FACT-L (Functional Assessment of Cancer Therapy - Lung)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment</measure>
    <time_frame>approx. 60 months</time_frame>
    <description>G8-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment</measure>
    <time_frame>approx. 60 months</time_frame>
    <description>Timed up &amp; go (test of basic functional mobility)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment</measure>
    <time_frame>approx. 60 months</time_frame>
    <description>6MWT (6 minutes walk test)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Metastatic Lung Cancer</condition>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>Lung Adenocarcinoma Metastatic</condition>
  <condition>Large Cell Lung Carcinoma Metastatic</condition>
  <arm_group>
    <arm_group_label>Control Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3 Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2 D1,D8) Q3W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Frail or elderly patients with metastatic NSCLC; CARG- Score ≤ 3
Induction:Carboplatin (AUC 5.0; D1) + nab-Paclitaxel (100mg/m2) D1,D8; Q3W [2 cyc] followed by durvalumab (1125 mg; Q3W) [ 2 cyc] Maintenance:durvalumab (1500 mg) Q4W</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Frail or elderly patients with metastatic NSCLC; CARG- Score &gt; 3
Induction: Vinorelbine (30 mg/m2; D1+D8) Q3W [ 2 cyc] or Gemcitabine (1000 mg/m2; D1+D8) Q3W [ 2 cyc] followed by durvalumab (1125 mg) Q3W [2 cyc] Maintenance:durvalumab (1500 mg; Q4W)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Frail or elderly patients with metastatic NSCLC; CARG- Score &gt; 3
Vinorelbine (30 mg/m2; D1+D8) Q3W or Gemcitabine (1000 mg/m2; D1+D8) Q3W</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Induction: (1125 mg) cycle Q3W Maintenance: (1500 mg) cycle Q4W</description>
    <arm_group_label>Experimental Arm B</arm_group_label>
    <arm_group_label>Experimental Arm C</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinorelbine</intervention_name>
    <description>(30 mg/m2 D1 + D8 as infusion) cycle Q3W</description>
    <arm_group_label>Control Arm D</arm_group_label>
    <arm_group_label>Experimental Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>(1000 mg/m2 D1 + D8 as infusion) cycle Q3W</description>
    <arm_group_label>Control Arm D</arm_group_label>
    <arm_group_label>Experimental Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel</intervention_name>
    <description>(100 mg/m2 intravenous infusion over 30 minutes on D1, D8) cycle Q3W</description>
    <arm_group_label>Control Arm A</arm_group_label>
    <arm_group_label>Experimental Arm B</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>(AUC = 5 mg•min/mL on Day 1) cycle Q3W</description>
    <arm_group_label>Control Arm A</arm_group_label>
    <arm_group_label>Experimental Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent and any locally-required authorization (EU Data Privacy
             Directive in the EU) obtained from the subject prior to performing any
             protocol-related procedures, including screening evaluations

          2. Age ≥ 70 years at time of study entry and/or Charlson-Comorbidity-Index (CCI) &gt;1
             and/or Performance status ECOG &gt;1

          3. Histologically confirmed diagnosis of metastatic NSCLC and no targetable molecular
             alterations (EGFRwt; ALKtransl-) and not amenable to cisplatinum-based
             standard-combination chemotherapy.

          4. Patients with measurable disease (at least one uni-dimensionally measurable target
             lesion not previously irradiated, by CT-scan or MRI) according to Response Evaluation
             Criteria in Solid Tumors (RECIST 1.1) are eligible.

          5. A formalin fixed, paraffin-embedded (FFPE) tumor tissue block (fresh or archival less
             than 3 years old or recent) or a minimum of 10 unstained slides of tumor sample
             (slices must be less than 90 days old and collected on SuperFrost slides provided by
             the sponsor) must be available for biomarker (PD-L1) evaluation. Biopsy should be
             excisional, incisional or core needle. Fine needle aspiration is inappropriate.

          6. No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Patients who
             have received prior platinum-containing adjuvant, neoadjuvant, or definitive
             chemoradiation for locally advanced disease are eligible, provided that progression
             has occurred &gt;6 months from last therapy.

          7. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and
             palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and
             patient recovered from toxic effects or associated adverse events.

          8. Adequate blood count, liver-enzymes, and renal function:

               -  Haemoglobin ≥ 9.0 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)

               -  Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)

               -  Serum bilirubin ≤ 1.5 x ULN. This will not apply to subjects with confirmed
                  Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is
                  predominantly unconjugated in the absence of hemolysis or hepatic pathology), who
                  will be allowed only in consultation with their physician.

               -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver
                  metastases are present, in which case it must be ≤ 5x ULN

               -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault
                  1976) or by 24-hour urine collection for determination of creatinine clearance

          9. Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits, examinations including follow up
             and appropriate contraception

        Exclusion Criteria:

          1. Mixed small-cell lung cancer and NSCLC histology

          2. Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3
             electrocardiograms (ECGs) using Fredericia's correction

          3. History of another primary malignancy except local prostate cancer without need for
             systemic treatment (e.g. active surveillance, operation without need for adjuvant
             treatment) and malignancies treated with curative intent and with no known active
             disease &gt;2 years befor the first dose of study drug and of low potential risk for
             recurrence, e.g. adequately treated non-melanoma skin cancer or lentigo maligna
             without evidence of disease, adequately treated carcinoma in situ without evidence of
             disease (e.g. cervical cancer in situ)

          4. Pre-existing peripheral neuropathy of Grade ≥ 2

          5. Brain metastasis or spinal cord compression unless asymptomatic or treated and stable
             off steroids and anti-convulsants for at least 1 month prior to study treatement.

          6. Active or prior documented autoimmune disease within the past 2 years. NOTE: Subjects
             with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within
             the past 2 years) are not excluded.

          7. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis)

          8. History of primary immunodeficiency

          9. History of allogeneic organ transplant

         10. History of hypersensitivity to durvalumab or any excipient

         11. History of hypersensitivity to any of the comparator agents

         12. Medication that is known to interfere with any of the agents applied in the trial.

         13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any subject known to have evidence of acute or chronic
             hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric
             illness/social situations that would limit compliance with study requirements or
             compromise the ability of the subject to give written informed consent

         14. Clinical diagnosis of active tuberculosis

         15. Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving durvalumab

         16. Male patients of reproductive potential who are not employing an effective method of
             birth control (failure rate of less than 1% per year)

         17. Any condition that, in the opinion of the investigator, would interfere with
             evaluation of study treatment or interpretation of patient safety or study results

         18. Participation in another clinical study with an investigational product during the
             last 30 days before inclusion

         19. Any previous treatment with a PD-1 or PD-L1 inhibitor, including durvalumab

         20. Current or prior use of immunosuppressive medication within 28 days before the first
             dose of durvalumab, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid

         21. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy,
             endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal
             antibodies, other investigational agent) ≤ 21 days prior to the first dose of study
             drug or ≤4 half-lifes of the agent administered, which ever comes first.

         22. Previous enrollment or randomization in the present study.

         23. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca
             staff and/or staff of sponsor and study site)

         24. Patient who might be dependent on the sponsor, site or the investigator

         25. Patient who has been incarcerated or involuntarily institutionalized by court order or
             by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.

         26. Patients who are unable to consent because they do not understand the nature,
             significance and implications of the clinical trial and therefore cannot form a
             rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Kuon, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, Heidelberg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Magda Krejczy</last_name>
    <phone>+49 30 8145 344 40</phone>
    <email>magda.krejczy@aio-studien-ggmbh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonas Kuon, Dr</last_name>
    <email>jonas.kuon@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gesundheitszentrum St. Marien GmbH</name>
      <address>
        <city>Amberg</city>
        <zip>92224</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludwig Fischer von Weikersthal, Dr.</last_name>
      <phone>+49 9621 381637</phone>
      <email>weikersthal.ludwig@klinikum-amberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Berlin Mitte</name>
      <address>
        <city>Berlin-Mitte</city>
        <zip>13359</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent van Laak, Dr.</last_name>
      <phone>+49 30 30356303</phone>
      <email>v.laak@drk-kliniken-berlin.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ev. Lungenklinik Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Grohé, Prof. Dr.</last_name>
      <phone>+49 30 94802112</phone>
      <email>christian.grohe@pgdiakonie.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Bernhard, Prof. Dr.</last_name>
      <phone>+49 61511076651</phone>
      <email>helga.bernhard@mail.klinikum-darmstadt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl-Gustav-Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wermke, Dr.</last_name>
      <phone>+49 351 4587566</phone>
      <email>martin.wermke@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen</name>
      <address>
        <city>Esslingen</city>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Faehling, Dr.</last_name>
      <phone>+49 711 31032402</phone>
      <email>m.faehling@klinikum-es.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Gleiber, Dr.</last_name>
      <phone>+49 69 63016337</phone>
      <email>wolfgang.gleiber@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Schillerhöhe</name>
      <address>
        <city>Gerlingen</city>
        <zip>70839</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kimmich, Dr.</last_name>
      <phone>+49 7156 2037719</phone>
      <email>martin.kimmich@klinik-schillerhoehe.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Boesche, Dr.</last_name>
      <phone>+49 3834 8680683</phone>
      <email>boeschem@uni-greifswald.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkodoc GmbH</name>
      <address>
        <city>Gütersloh</city>
        <zip>33332</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Schütt, PD Dr.</last_name>
      <phone>+49 5241 8328150</phone>
      <email>schuett@onkologie-guetersloh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle Dölau</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Schütte, Prof. Dr.</last_name>
      <phone>+49 345 5591440</phone>
      <email>wolfgang.schuette@Martha-Maria.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonas Kuon, Dr</last_name>
      <phone>+49 6221 396 8008</phone>
      <email>Jonas.Kuon@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Serke, Dr</last_name>
      <phone>+49 2372 9082201</phone>
      <email>monika.serke@lkhemer.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Vincentius-Diakonissen-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Meyer zum Büschenfelde, Prof. Dr.</last_name>
      <phone>+49 721 81083014</phone>
      <email>christian.mzb@vincentius-ka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walburga Engel-Riedel, Dr.</last_name>
      <phone>+49 221 890713962</phone>
      <email>engelriedelw@kliniken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ortenau-Klinikum Lahr</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ev. Diakonissenkrankenhaus Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Gütz, Dr.</last_name>
      <phone>+49 341 4443621</phone>
      <email>Sylvia.Guetz@ediacon.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Ulmer, Dr.</last_name>
      <phone>+49 7141 9994467</phone>
      <email>matthias.ulmer@kliniken-lb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH</name>
      <address>
        <city>Löwenstein</city>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.R. Fischer, PD Dr.</last_name>
      <phone>+49 7130 154207</phone>
      <email>jr.fischer@klinik-loewenstein.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Modest, PD Dr.</last_name>
      <phone>+40 89 44000</phone>
      <email>dominik.modest@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pius Hospital Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26121</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Griesinger, Prof. Dr.</last_name>
      <phone>+49 441 2291691</phone>
      <email>frank.griesinger@pius-hospital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Moosmann, Dr.</last_name>
      <phone>+49 941 3692151</phone>
      <email>nicolas.moosmann@barmherzige-regensburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>&quot;Klinikum Rheine</name>
      <address>
        <city>Rheine</city>
        <zip>48341</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Dickgreber, Dr.</last_name>
      <phone>+49 5971-422701</phone>
      <email>n.dickgreber@mathias-spital.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Denzlinger, Prof. Dr.</last_name>
      <email>claudio.denzlinger@vinzenz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Brüder</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinz Kirchen, Dr.</last_name>
      <phone>+49 651 2082662</phone>
      <email>h.kirchen@bk-trier.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Kropf-Sanchen, Dr.</last_name>
      <email>cornelia.kropf-sanchen@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anja Rückert, Dr.</last_name>
      <phone>+49 7721-934013</phone>
      <email>anja.rueckert@sbk-vs.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SHG-Kliniken-Völklingen</name>
      <address>
        <city>Völklingen</city>
        <zip>66333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harald Schäfer, Prof. Dr.</last_name>
      <phone>+49 6898 122351</phone>
      <email>h.schaefer@vk.shg-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-Onkologische Praxis Würselen</name>
      <address>
        <city>Würselen</city>
        <zip>52146</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Maintz, Dr.</last_name>
      <phone>+49 2405-48920</phone>
      <email>c.maintz@aachen-onkologie.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Würzburg Mitte gGmbH</name>
      <address>
        <city>Würzburg</city>
        <zip>97074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jens Kern, Dr.</last_name>
      <phone>+49 931 7912814</phone>
      <email>jens.kern@missioklinik.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>AIO - Working Group for Medical Oncology from the German Cancer Society</description>
  </link>
  <link>
    <url>http://www.aio-studien-ggmbh.de</url>
    <description>AIO-Studien-gGmbH</description>
  </link>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>July 27, 2018</last_update_submitted>
  <last_update_submitted_qc>July 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Non small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

